@article{oai:sucra.repo.nii.ac.jp:00017023,
 author = {金子, 秀},
 journal = {社会科学論集, SHAKAIKAGAKU－RONSHU (The Social Science Review)},
 month = {},
 note = {Japanese big pharmaceutical companies have performed M&A in order to increase revenue and profit since 2000. However, their profitability was in decline between 2006 and 2012.
This paper focuses on value-added productivity and examines the factors leading to the decline of profitability in these companies. As a basis for labor productivity measures, value added per employee is used to measure the effectiveness of an organization. With respect to this measure, it is not clear why value-added productivity was in decline in these companies between 2006 and 2012.
Therefore, the author proposes value added by personnel expenses as a measure of value-added productivity, which is composed as two factors: capital intensity of labor × capital productivity.
On the other hand, capital productivity ＝ sales to operating assets × value added to sales. The findings are as follows: M&A increased capital intensity of labor through the growth of intangible assets (e. g. goodwill). Therefore, M&A negatively impacted value-added productivity.
In this situation, Astellas Pharmaceutical and Eisai Pharmaceutical are trying to improve capital productivity through reconstruction of R&D organization with respect to increasing sales to operating assets and value added to sales., １．本研究の課題と方法
２．労働生産性指標の検討
３．付加価値生産性の理論と測定
４．医薬品企業における付加価値生産性の分析
５．結論, text, application/pdf},
 pages = {179--209},
 title = {付加価値生産性の研究 : 医薬品企業の事例《研究ノート》},
 volume = {142},
 year = {2014},
 yomi = {カネコ, シゲル}
}